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Abstract 
This report analyses whether substances classified for specific target organ toxicity (STOT) according Regulation (EC) No 1272/2008 on 
Classification, Labelling and Packaging, in particular those causing immunotoxic or neurotoxic effects, would be eligible to be identified 
as substances of very high concern (SVHC) under the 'equivalent level of concern' route set out in Article 57(f) of REACH Regulation (EC) 
No 1907/2006 (Registration, Evaluation, Authorisation and Restriction of Chemicals). This document attempts to identify, characterise 
and compare the 'level of concern' that exists for immunotoxic and neurotoxic substances with that of CMRs (carcinogens, mutagens 
and/or reproductive toxicants). The comparison considers the seriousness, irreversibility and delay of hazardous effects, together with 
other factors, such as the quality of life affected, consequences for society and the possibility to derive a safe concentration.  
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Preface 
This report has been prepared in the frame of an Administrative Arrangement between the 
Directorate-General Environment (DG ENV) and the Joint Research Centre (JRC), Institute for Health 
and Consumer Protection (IHCP) on 'Scientific and technical support to safety assessment of 
chemicals'. It analyses whether substances classified for specific target organ toxicity (STOT) 
according Regulation (EC) No 1272/2008 on Classification, Labelling and Packaging, in particular 
those causing immunotoxic or neurotoxic effects, would be eligible to be identified as substances of 
very high concern under the ‘equivalent level of concern’ route set out in Article 57(f) of REACH 
Regulation (EC) No 1907/2006 (Registration, Evaluation, Authorisation and Restriction of Chemicals). 
After an internal review by JRC-IHCP and DG ENV, a draft version of this report was circulated to 
participants of the 'Sensitiser and other equivalent level of concern substances (ELoC) Coordination 
Group (SCG)' organised by ECHA. Comments received from the SCG were taken into consideration in 
this final version. 
We would like to thank the SCG experts and the colleagues from DG ENV, ECHA and JRC, especially 
from the Systems Toxicology and Chemical Assessment and Testing Units, for their useful comments. 
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Executive summary 
Article 57 of REACH Regulation (EC) No 1907/2006 (Registration, Evaluation, Authorisation and 
Restriction of Chemicals) specifies the criteria for substances to be included in Annex XIV, the 'List of 
Substances Subject to Authorisation' under REACH, also known as Substances of Very High Concern 
(SVHC). According to Article 57 (a-e) carcinogens, mutagens, and chemicals toxic for reproduction 
(CMR) as well as substances which are persistent, bioaccumulative and toxic (PBT), or very persistent 
and very bioaccumulative (vPvB) may be considered SVHC. In addition endocrine disruptors and 
other chemicals which give rise to an equivalent level of concern (ELoC) (equivalent to CMRs, PBT or 
vPvB), and for which there is scientific evidence of probable serious effects to human health or 
environment can be identified as SVHC on a case-by-case basis, as stated in Article 57(f) of this 
regulation. There is currently no specific guidance or established criteria available and therefore case 
studies for specific toxicity endpoints are being prepared to facilitate this ELoC comparison. 
This paper aims at analysing whether substances classified in the Regulation (EC) No 1272/2008 on 
Classification, Labelling and Packaging (CLP) as Specific Target Organ Toxicity (STOT) Category 1 and 
Category 2 (single or repeated exposure (STOT-SE or STOT-RE)), particularly immunotoxicants and 
neurotoxicants, fulfil the proposed criteria to support the identification of these compounds as SVHC 
according to Art. 57(f). It attempts to identify, characterise and compare the level of concern that 
exists for immunotoxicants and neurotoxicants with that of CMRs. This assessment is based on the 
consideration that in certain cases it may be demonstrated that the impacts caused by 
immunotoxicants and neurotoxicants on the health of the affected individuals and on the society as 
a whole, can be comparable to those elicited by CMRs. To determine an equivalent level of concern 
to CMRs, the comparison assessment focuses on the seriousness, irreversibility and delay of health 
effects but considers also other factors such as effects on quality of life, societal concerns or the 
possibility to derive a 'safe concentration'.  
The assessment suggests that some substances showing immunotoxic or neurotoxic effects could 
present an 'equivalent level of concern' to CMRs and potentially be identified as SVHC according to 
the Art. 57(f) route in REACH. For both, neurotoxic and immunotoxic substances a case-by-case 
justification considering the hazard assessment and evidence of an equivalent level of concern is 
necessary. Societal concern and impairment of quality of life can be a consequence of exposure to 
neurotoxicants or immunotoxicants particularly for a vulnerable part of the population, including 
children and elderly as well as people with a challenged immune system, which may be more 
sensitive to lower concentrations. A particular challenge is that for both, immunotoxic and 
neurotoxic effects, the relationship between chemical exposure and effect may not always be 
obvious. In general, identification of SVHC that exert immunotoxic effects is more complex than of 
substances with neurotoxic effects, due to the lack of EU methods or OECD test guidelines.  
Neurotoxicity or immunotoxicity effects occurring at dose ranges that are critical for the respective 
STOT-SE/RE classification (category 1 and 2) should be primarily considered for SVHC identification. 
This paper underlines the importance of a harmonised classification as a STOT-SE/RE substance for 
these specific effects before starting any SVHC identification. However for the 'equivalent level of 
concern' evaluation and justification also other factors need to be taken into account on a case-by-
case basis.  
10 
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1. Background 
The European Commission is committed to have all relevant currently known Substances of Very 
High Concern (SVHC) included in the Candidate list (Annex XIV o REACH) by 20201. The objective is to 
determine the relevance of the substances already recognised as SVHC and to identify potential new 
ones. To achieve this target, the Commission and ECHA with the support of Member States 
Competent Authorities for REACH drafted a Roadmap in which screening of dossiers and evaluation 
of Risk Management Options (RMO) strategies are fundamental steps in the identification of 
relevant SVHC that later on may be subject to an authorisation process. 
According to Article 57 of the REACH Regulation (EC) No 1907/2006, substances of very high concern 
are substances that meet the criteria for classification as carcinogens, mutagens, and chemicals toxic 
for reproduction (CMR) as well as substances which are persistent, bioaccumulative and toxic (PBT), 
or very persistent and very bioaccumulative (vPvB) (Art.57 (a-e)). Article 57 (f) applies to endocrine 
disruptors and other chemicals which give rise to an equivalent level of concern to CMRs or PBTs or 
vPvBs, for which there is scientific evidence of probable serious effects to human health or 
environment […] and which are identified on a case-by-case basis. Such substances may be identified 
as SVHCs in accordance with the procedure set out in Article 59.  
This paper aims at analysing whether substances classified for specific target organ oxicity (STOT), in 
particular those causing immunotoxic or neurotoxic effects, are eligible to be identified as 
substances of very high concern. This document is thus in line with the objective of the Roadmap 
2020 drafted by the EC to define a process or methodology […] on how to assess the different groups 
of potential SVHCs, in particular with the purpose to identify relevant SVHCs falling under Article 57 
(f) of REACH.  
This document introduces the steps for the general identification of SVHC and the proposed factors 
to assess an equivalent level of concern to CMRs. Thereafter it presents the criteria for STOT-SE/RE 
classification and indicates a list of methods and technical challenges found in the hazard 
identification process for neurotoxicants and immunotoxicants. The main part of the document is a 
systematic assessment of the proposed ELoC factors to evaluate their applicability in the 
identification of neurotoxicants and immunotoxicants as SVHC. Annex I includes an extended 
description of criteria for STOT-SE/RE classification according CLP; Annex II describes adverse health 
effects caused by immunotoxicants and neurotoxicants. Finally, examples for chemicals with 
potential neurotoxic effects are presented in Annex III. 
  
                                                            
1
 Council of the European Union: Roadmap for SVHCs identification and implementation of REACH Risk Management measures from now 
to 2020 http://register.consilium.europa.eu/pdf/en/13/st05/st05867.en13.pdf 
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2. General identification and assessment of SVHC 
The process of identification of SVHC is, in general, based on intrinsic hazard properties of 
substances. Thus, when possible, the consultation of the harmonised classification and criteria 
provided in Annex I of CLP (Regulation (EC) No 1272/2008 on classification, labelling and packaging 
of substances and mixtures) is useful as a starting point.  
For substances under Art. 57(a-e), hazard identification and characterisation in accordance with CLP 
regulation is the first step in the process of SVHC identification. In the case of the substances 
following the route Art. 57(f), it would, however, not be a straightforward task. Along with the 
hazard identification, a substance may be identified as SVHC if it is demonstrated, on a case-by-case 
basis, that it shows adverse effects on human health of equivalent level of concern (ELoC) compared 
to CMR effects2. Art. 57 (f) was envisaged as a safety net to control other potential risks than those 
covered by Art. 57(a-e), and little guidance is provided to determine the level of concern and assist 
the regulators in the identification of SVHC substances based on equivalent concern. 
With the purpose to provide support in this task, a workshop was organised in March 2012 by the 
German institutions, BfR (Federal Institute for Risk Assessment) and BAuA (Federal Institute for 
Occupational Safety and Health)3. In this meeting, some considerations and principles were 
discussed in the context of establishing a harmonised and general concept for SVHC identification 
according to the mentioned Art. 57 (f) route4. Factors identified as relevant for the identification of a 
substance as a SVHC and for comparison of the ELoC with CMR substances were: seriousness of 
effect (e.g. partly or non-reversible effects, delayed time lag following exposure or postnatal 
developmental toxicity), strength of evidence, relevance for humans and potency. 
The first group of substances discussed for identification as SVHC via Art. 57 (f) route (excluding 
endocrine disruptors) were chemicals with respiratory and skin sensitising properties. ECHA 
prepared a discussion paper in which they discussed sensitisers, as a potential group to be identified 
as SVHC and concluded that the relevant factors mentioned in the BfR/BAuA workshop could be 
used to demonstrate an 'equivalent level of concern' to CMRs5. The document also advocated 
getting a harmonised classification and labelling under CLP before suggesting identification of the 
substance concerned as SVHC, and in case a harmonised and general concept cannot be followed, a 
case-by-case justification for each individual substance to be identified as SVHC was suggested by 
different partners during the discussions. 
  
                                                            
2
 In this document ELoC is only considered in relation to human health concerns. 
3
 BfR and BAuA workshop on 'REACH Article 57 (f): Non-Endocrine Disrupting Human Health Hazards Leading to SVHC Identification'. 
(http://www.bfr.bund.de/cm/343/reach-article-57-buchstabe-f-non-endocrine-disrupting-human-health-hazards-leading-to-svhc-
identification.pdf) 
4
 http://www.baua.de/en/Topics-from-A-to-Z/Hazardous-Substances/Workshops/REACH-2012.html  
5
 Identification of substances as SVHCs due to equivalent level of concern to CMRs (Article 57(f)) – sensitisers as an example; 
http://echa.europa.eu/documents/10162/19126370/dp_sensitisers_final_en.pdf 
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3. Identification of STOT-SE/RE classified substances as SVHC 
The current document focuses on substances classified as specific target organ toxicity (STOT) and 
the objective is to analyse whether such compounds present hazard characteristics that may give 
rise to an ELoC to CMRs. This is based on the assumption, that any severe, delayed and/or persistent 
damage to organs or organ systems falling under the STOT-SE/RE criteria may give rise to ELoC to 
CMRs. This document focuses specifically on immunotoxic and neurotoxic properties as these effects 
are considered of specific concern. 
3.1. STOT classification  
Specific target organ toxicity, according to the CLP Regulation (Annex I: section 3.8.1.1 and 3.9.1.1), 
is defined as specific, [non-lethal]6 target organ toxicity arising from a single [or repeated] exposure 
to a substance or mixture7. All significant health effects that can impair function, both reversible and 
irreversible, immediate and/or delayed and not specifically addressed by [other hazard categories]. 
Specific target organ toxicity can occur by any route that is relevant for humans and encompasses 
several adverse effects that may be severe, delayed and/or irreversible such as haemotoxicity, 
hepatotoxicity, nephrotoxicity, neurotoxicity and immunotoxicity, but also transient effects such as 
respiratory tract irritation and narcotic effects. Effects falling under another hazard category such as 
acute toxicity, skin corrosion/irritation, serious eye damage/eye irritation, respiratory or skin 
sensitisation, germ cell mutagenicity, carcinogenicity, reproductive toxicity or aspiration toxicity are 
covered by other classification criteria and, therefore they should not be classified as STOT.  
Substances presenting STOT effects are classified differently depending on whether these adverse 
effects are detected after single or repeated exposure and consequently would be classified as STOT-
single exposure (STOT-SE) or STOT-repeated exposure (STOT-RE), respectively (Table 1). In some 
cases, toxic effects classified as STOT-SE could be mistaken as acute toxicity effects and care should 
be taken to avoid 'double classification'. The main criterion to differentiate these two classifications 
is lethality; classification for acute toxicity is assigned to lethal effects, while non-lethal severe 
effects in a single organ or biological system but also generalised changes of a less severe nature 
involving several organs, delayed and/or irreversible toxic effects after single exposure are classified 
as STOT-SE. 
  
                                                            
6
 This criterion only applies for STOT-SE (single exposure). 
7
 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02008R1272-20131201&from=EN 
14 
Table 1 Classification and labelling for specific target organ toxicity after single and repeated exposure 
  
As the range of possible STOT effects is broad, this document will be centred on the evaluation of 
substances with neurotoxic (including effects on special senses and effects on the peripheral 
nervous system) or immunotoxic effects as potential candidates to be identified as SVHC (Annex II: 
Adverse health effects caused by immunotoxicants and neurotoxicants). This is motivated by the fact 
that these effects, besides inducing direct toxic effects, may lead to cognitive and behavioural 
impairment or increased sensibility sensitivity to infectious or other diseases, which may have 
considerable consequences on the quality of life and create societal cost in terms of the profound 
health compromise.  
This document focuses on substances classified as STOT-SE/RE 1 and 2, which cause or may cause 
serious damage to organs through single or repeated exposure. Substances showing reversible and 
less serious effects such as respiratory irritation and drowsiness or dizziness effects, classified as 
STOT-SE 3, are not considered for SVHC identification. 
Hazard class Hazard 
category 
Abbreviation GHS pictogram Signal 
word 
Hazard 
code 
Hazard statement 
Specific target 
organ toxicity 
Single  
exposure 
Category 1 STOT SE 1 
 
Danger H370 Causes damage to organs (or 
state all organs affected, if 
known) (state route of 
exposure if it is conclusively 
proven that no other routes of 
exposure cause the hazard) 
Category 2 STOT SE 2 
 
Warning H371 May cause damage to organs 
(or state all organs affected, if 
known) (state route of 
exposure if it is conclusively 
proven that no other routes of 
exposure cause the hazard) 
Category 3 STOT SE 3 
 
Warning H335 May cause respiratory 
irritation 
H336 May cause drowsiness or 
dizziness 
Specific target 
organ toxicity 
Repeated 
exposure 
Category 1 STOT RE 1 
 
Danger H372 Causes damage to organs 
(state all organs affected, if 
known) through prolonged or 
repeated exposure (state 
route of exposure if it is 
conclusively proven that no 
other routes of exposure 
cause the hazard) 
Category 2 STOT RE 2 
 
Warning H373 May cause damage to organs 
(state all organs affected, if 
known) through prolonged or 
repeated exposure (state 
route of exposure if it is 
conclusively proven that no 
other routes of exposure 
cause the hazard) 
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3.1.1.  Identification of hazard information for STOT-SE/RE substances 
The identification of human health hazard generally comes from animal studies or where available 
from human experience/incidents. Information may also be obtained using read-across from 
structurally-related substances and from appropriate in vitro or in silico models, if applicable. Animal 
tests involve single or repeated exposure via any relevant route of exposure8. According to CLP 
guidance, acute toxicity studies in animals may provide hazard information about toxic effects of a 
substance on target tissues/organs that reach the classification as STOT-SE. Furthermore, STOT-RE 
effects can be determined using repeated dose animal studies treated during 28 day, 90 day or 
lifetime studies (up to 2 years), together with the information provided by other long-term studies 
(carcinogenicity, neurotoxicity or reproductive toxicity). During the assessment of potential STOT 
substances, adverse effects in more than one organ should be considered, and due to the difficulties 
to interpret some results, in most cases expert judgement is required to follow a weight-of-evidence 
approach considering all the data available. 
Standard oral (but not standard dermal or inhalation) 28-day and 90-day toxicity studies include 
endpoints capable of detecting evidence of neurotoxic and immunotoxic effects. In addition, in 2011 
OECD adopted as a Test Guideline the 'Extended One Generation Reproductive Toxicity study 
(EOGRTS)' (OECD TG 443). This study is designed not only to provide information on reproductive 
toxicity but also includes other endpoints such as developmental neurotoxicity, developmental 
immunotoxicity, and endocrine-mediated toxicity. Immunotoxic and neurotoxic effects identified 
using OECD TG 443, TG 426 (Developmental Neurotoxicity Study) or other developmental studies 
capable of identifying these effects as described below, would however be considered as 
developmental effects leading to a hazard classification under the category of reproductive toxicants 
in CLP regulation and would thus already be considered as SVHC according to Art 57 (c). Therefore, 
for the identification of neurotoxic and immunotoxic hazard other studies may be necessary to 
further investigate the same effects9. In this regard, international guidance documents are available 
to assist in the evaluation of available data and to recommend tests to determine STOT specific 
effects such as neurotoxicity and immunotoxicity10,11,12,13.  
3.1.2. Identification of hazard information for neurotoxicants 
Indicators of neurotoxicity include clinical observations, a functional observational battery, motor 
activity assessment and histopathological examination of the spinal cord and the sciatic nerve.  
The identification of chemicals with potential to cause damage on the developing brain is performed 
following OECD TG 426 (Developmental Neurotoxicity Study, mostly in rats) and on the matured 
nervous system according to TG 424 (Neurotoxicity Study in rodents). The delayed neurotoxicity 
                                                            
8
 ECHA guidance to Regulation (EC) No 1272/2008 (CLP Regulation) http://echa.europa.eu/documents/10162/13562/clp_labelling_en.pdf 
9
 ECHA Guidance on information requirements and Chemical Safety Assessment 
(http://echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf) 
10
 Harmonization Project Document No. 10: Guidance for immunotoxicity risk assessment for chemicals (WHO/IPCS) 
11
 OECD series on testing and assessment: Number 20, Guidance Document for Neurotoxicity Testing (2004) 
12
 EPA Risk Assessment Forum: Guidelines for Neurotoxicity Risk Assessment (1998) 
13
 Environmental Health Criteria 223. Neurotoxicity risk assessment for human health: principles and approaches, 2001 
(http://www.inchem.org/documents/ehc/ehc/ehc223.htm#_223241000) 
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study in hens (OECD TG 419) is specifically designed to be used in the assessment and evaluation of 
the neurotoxic effects of organophosphorus substances.  
To obtain information on potential neurotoxic effects of chemicals, the OECD Guidance document 
for neurotoxicity testing (2004)14 suggested other OECD Test Guidelines including those for single 
dose toxicity (e.g. OECD TG 40215, TG 40316, TG 42017, TG 42318 and TG 42519), repeated dose toxicity 
(e.g. OECD TG 40720 and TG 40821), as well as Test Guidelines specifically developed for the study of 
neurotoxicity in adult and young laboratory animals [OECD Test Guidelines (TG 418 and TG 419) for 
Delayed Neurotoxicity of Organophosphorus Substances and OECD Test Guideline for 
Developmental Neurotoxicity (TG 426), OECD Test Guideline for Combined Repeated Dose Toxicity 
Study with Reproduction/Developmental Toxicity Screening Test (TG 422)] 22. The Biocidal Products 
Regulation (BPR) (EU) No 528/201223 also gives recommendations on the toxicological information 
required to support the approval of an active substance. In the case of the evaluation of 
neurotoxicity, the legal text mentions the preferred test species (rat, except for delayed 
neurotoxicity where adult hens are suggested) or specific tests such as cholinesterase activity test24. 
It is important to indicate that neurotoxicity not only includes effects on the central nervous system 
but also serious damage (morphological or functional or both) of the eye (retina, eye nerve), ear 
(hearing), and effects affecting the sense of smell and the peripheral nervous system. Examinations 
in the standard OECD test guideline are often not sufficient for the hazard characterisation or even 
identification of these effects. 
3.1.3. Identification of hazard information for immunotoxicants 
Indicators of immunotoxicity include changes of haematological parameters, serum globulin levels, 
organ weights alterations and/or histopathological changes in immune organs such as spleen, 
thymus, lymph nodes and bone marrow.  
In the case of immunotoxicants, no specific OECD TG guidelines or EU methods are available to 
characterise immunotoxic properties and information on immunosuppression, immunostimulation 
or autoimmune diseases may not always be derived from available standard test guidelines. The 
information requirements in the BPR (EU) (EU) No 528/2012 regarding immunotoxicity mention 
direct observation (e.g. clinical cases) to assess any pathogenicity and infectiveness to humans and 
                                                            
14
 http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?doclanguage=en&cote=env/jm/mono(2004)25 
15
 OECD (1987),Test No. 402: Acute Dermal Toxicity, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing. 
16
 OECD (2009),Test No. 403: Acute Inhalation Toxicity, OECD Guidelines for the Testing of Chemicals, Section 4, OECD Publishing. 
17
 OECD (2002),Test No. 420: Acute Oral Toxicity - Fixed Dose Procedure, OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. 
18
 OECD (2002),Test No. 423: Acute Oral toxicity - Acute Toxic Class Method, OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. 
19
 OECD (2008),Test No. 425: Acute Oral Toxicity: Up-and-Down Procedure, OECD Guidelines for the Testing of Chemicals, Section 4, OECD 
Publishing. 
20
 OECD (2008),Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing of Chemicals, Section 
4, OECD Publishing. 
21
 OECD (1998),Test No. 408: Repeated Dose 90-Day Oral Toxicity Study in Rodents, OECD Guidelines for the Testing of Chemicals, Section 
4, OECD Publishing. 
22
 OECD series on testing and assessments (Number 20): Guidance Document for neurotoxicity testing. ENV7JM7MONO(2004)25. 
23
 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02012R0528-20140425&from=EN 
24
 Biocidal Product Regulation (BPR, Regulation (EU) No 528/2012). 
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other mammals under conditions of immunosuppression. Information from immunosuppression 
tests included in other international guidance documents (e.g. EMA (ICH Topic 8 from 2006)25, EPA 
(OPPTS 870.7800 from 1998)26) may also be considered. 
Due to the lack of EU/OECD methods, a better identification and distinction of effects associated 
with the immune system (e.g. immunosuppression and immunostimulation) may only be derived 
from enhanced examinations included in repeated dose toxicity studies 27 . Also, as for the 
neurotoxicants, the outcome of the assessment of developmental immunotoxicity in EOGRTS may 
be informative on potential effects of immunotoxicants in adults. 
For specific immunological effects such as respiratory and skin sensitisation, partly validated tests 
are available. These have, however, a separate classification, and will therefore not be addressed in 
this document; the criteria to identify these substances as SVHC have been previously examined in 
the above-mentioned ECHA discussion paper.  
Specific effects and their potency, supporting the classification for Category 1 and 2 of STOT-SE/RE in 
CLP guidance, together with specific adverse effects of immunotoxicants and neurotoxicants are 
discussed in more detail in classification in this document.  
  
                                                            
25
 ICH Topic S 8 Immunotoxicity Studies for Human Pharmaceuticals. CHMP/167235/2004. 
26
 Health Effects Test Guidelines: OPPTS 870.7800 Immunotoxicity [EPA 712–C–98–351]: 
http://www.regulations.gov/#!documentDetail;D=EPA-HQ-OPPT-2009-0156-0049 
27
 Schulte, Agnes et.al. "Two Immunotoxicity Ring Studies According to OECD TG 407—Comparison of Data on Cyclosporin A and 
Hexachlorobenzene." Regulatory Toxicology and Pharmacology 36, 12–21 (2002). 
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4. 'Level of Concern' comparison 
The first step in the identification of a chemical as SVHC under Art. 57(f) is the hazard 
characterization, i.e. in the current case the identification as an immunotoxicant or neurotoxicant. 
This should enable a decision on a classification of the substance, if required. Hazard 
characterisation and classification per se however are not sufficient and an 'equivalent level of 
concern' compared to carcinogenic, mutagenic or reproductive toxic substances needs to be also 
demonstrated.  
The level of concern thus takes into account other factors in addition to hazardous properties, as 
stated in the ECHA discussion paper on the Identification of substances as SVHCs due to equivalent 
level of concern to CMRs (Article 57(f)) – sensitisers as an example are: […] the seriousness of the 
effects, the often irreversible nature of the effects, the consequences for society and the difficulty in 
performing concentration-based risk assessments (except for reproductive effects)28. Furthermore, 
the OECD Guidance document for neurotoxicity testing (2004) suggests that the level of concern of 
the neurotoxic effects should be based on type, severity, number and either full or partial reversibility 
of the effects. Chemicals which produce a clear and consistent pattern of neurotoxicity at lower dose 
levels than other organ/system toxicity are generally of higher concern than chemicals which produce 
only a few unrelated effects. 
To compare the level of concern of immune- and neurotoxicants with CMRs, this document builds on 
ECHA's discussion paper, in which the factors considered suitable to identify as to whether a 
substance with respiratory or skin sensitising properties may be identified as a SVHC have been 
evaluated. The same factors are discussed here to evaluate the level of concern for adverse effects 
elicited by exposure to immunotoxicants and neurotoxicants. The evaluation of these factors for 
CMRs presented in ECHA's paper (see text in italics) is included also in this document for 
comparative purposes. Furthermore, for clarity, the same outline as in ECHA's discussion paper has 
been followed: 
 Health effects (Section 4.1) 
- Type of possible health effects 
- Irreversibility of health effects 
- Delay of health effects 
 Other factors (Section 4.2) 
- Quality of life affected 
- Societal concern 
- Is derivation of a 'safe concentration' possible? 
 
Table 2 summarises the comparison based on these relevant factors among CMRs, immunotoxicants 
and neurotoxicants. This table also includes results from the previous analysis of ELoC on respiratory 
sensitisers, presented in ECHA’s document. 
                                                            
28
Identification of substances as SVHCs due to equivalent level of concern to CMRs (Article 57(f)) – sensitisers as an example 
(http://echa.europa.eu/documents/10162/13657/svhc_art_57f_sensitisers_en.pdf) 
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Table 2. ‘Level of Concern’ comparison between CMRs, Respiratory Sensitisation, Immunotoxicity and Neurotoxicity29  
 C & M R Respiratory Sensitisation Immunotoxicity Neurotoxicity 
Possible serious health 
effects? 
YES –  
 Serious & 
permanent organ 
dysfunction 
 Inheritable defects 
 Could lead to death 
YES –  
 Serious & permanent 
organ dysfunction 
 Malformations or death 
in (unborn) children 
YES –  
 Serious & permanent 
organ dysfunction 
 Permanent impairment 
of lung functions 
 Could lead to death 
YES –  
 Potential for serious & 
permanent organ dysfunction 
 Morphological abnormalities 
indicative for 
impairment/functional changes 
of immune system; increase of 
neoplastic diseases, and 
infections. Induction and 
increase of autoimmune 
diseases and allergic processes 
 Could lead to death  
YES –  
 Potential for serious & 
permanent organ dysfunction 
 Permanent 
impairment/functional changes 
of central or peripheral nervous 
system, other organs/organ 
systems including CNS 
depression and effects on 
special senses (motor, sight, 
hearing, sense of smell) as well 
as learning and memory. 
Irreversibility of health 
effects30? 
YES –  
 Irreversible effects 
YES –  
 Irreversible effects 
YES –  
 Induction phase of 
sensitisation 
 Elicitation phase of 
sensitisation -can lead 
to irreversible lung 
dysfunction 
YES –  
 Effects can be irreversible 
YES –  
 Effects can be irreversible, 
depending on dose and time of 
exposure (especially during 
susceptible life stages: 
postnatal development and 
aging) and/or half-life in body 
Delay of health effects? YES –  
 Long delay until 
effects manifest 
YES –  
 Medium delay until 
effects manifest 
YES –  
 Long/medium delay 
between induction and 
elicitation phases 
YES –  
 Delay (medium to long) until 
effects manifest possible 
YES –  
 Delay (medium to long) until 
effects manifest possible 
(depending on half-
life/accumulation in body) 
                                                            
29
 This table is a modification from Table 1 in ECHA’s paper on sensitisers (see the reference in footnote 28). 
30 Based on discussion if only irreversible effects classify as serious it was concluded that also some CR effects could be reversible (BfR and BAuA workshop on 'REACH Article 57 (f): Non-Endocrine Disrupting Human 
Health Hazards Leading to SVHC Identification'). 
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 C & M R Respiratory Sensitisation Immunotoxicity Neurotoxicity 
Quality of life impaired? YES –  
 Long-term illness 
limiting possibility 
of living a normal 
working and private 
life 
 Possible mental/ 
psychological 
impacts 
YES –  
 Children with 
developmental effects 
may need life-long 
medication/ support in 
their daily life 
 Life of parents also 
affected (emotional 
investment, care, 
financial costs) 
YES –  
 Long-term illness 
limiting the possibility 
of living a normal 
working and private 
life 
 Require long-term 
medication 
 Re-training of affected 
staff 
YES –  
 Long-term illness limiting 
possibility of living a normal 
working and private life 
 Possible mental/ psychological 
impacts (due to related effects 
such as reduced defense, 
cancer or autoimmune 
diseases) 
YES- 
 Long-term illness and reduced 
productivity limiting possibility 
of living a normal working and 
private life 
 Possible mental/ psychological 
impacts (due to effects on 
peripheral or central NS and 
special senses) 
Societal concern? YES –  
 Widespread 
concern about 
cancer 
 Cost implications 
for society in terms 
of healthcare 
 
YES –  
 Widespread concern 
about adverse effects in 
children 
 Cost implications for 
society in terms of 
healthcare 
 Disability 
YES –  
 Cost implications for 
society in terms of 
healthcare and 
retraining 
 Associated with 
disability 
YES –  
 Widespread concern about 
increase of infections or other 
related diseases 
 Cost implications for society in 
terms of healthcare (increase 
morbidity/premature mortality) 
 Disability 
YES –  
 Widespread concern about 
effects on the adult nervous 
system 
 Cost implications for society in 
terms of healthcare (increased 
risk of antisocial behavior as 
well as morbidity/premature 
mortality) 
 Disability 
Is derivation of a ‘safe 
concentration’ possible? 
NORMALLY NO - 
 ‘Zero risk’ only 
possible where no 
exposure 
NORMALLY YES -  
 Possible to determine a 
safe concentration 
 
NO –  
 Difficult to establish 
the threshold dose for 
induction and 
elicitation 
 Derivation of safe 
concentration is not 
routinely possible 
Potentially YES –  
 Possible to determine a safe 
concentration for certain 
substances 
 Difficult to establish a safe 
concentration for certain end-
points (U-shaped dose-response 
relationships) for certain 
substances 
Potentially YES -  
 Possible to determine a safe 
concentration for certain 
substances for adult 
neurotoxicity  
 Difficult to establish a safe 
concentration for certain end-
points (U-shaped dose-response 
relationships) for certain 
substances 
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4.1.  Health Effects 
4.1.1.  Type of possible health effects  
The initial point to identify a substance as SVHC is to evaluate whether the adverse effects exerted 
by the exposure to that substance are serious and relevant to humans. Classification under CLP 
regulation may provide information on the hazardous properties of substances and guidance to 
evaluate whether these effects may have a serious impact on human health and could be considered 
as equivalent level of concern to CMR substances (Cat. 1A/B). 
 In the case of carcinogens and mutagens, exposure to these substances has the potential to 
cause serious adverse health effects in a proportion of the population i.e. serious and 
permanent organ dysfunction, inheritable defects and/or death. 
 In the case of reproductive toxicants (development), exposure has the potential to cause 
serious adverse health effects in a proportion of the population i.e. serious and permanent 
organ dysfunction, defects and/or death. 
 In the case of immunotoxicants, exposure has the potential to cause serious adverse health 
effects in (a proportion of) the population. In principle, immunotoxicants can cause 
immunosuppression, immunostimulation or an abnormal immune response (such as 
autoimmunisation) (see Annex II: Adverse health effects caused by immunotoxicants and 
neurotoxicants). Immunosuppression effects can be linked to an increase of susceptibility to 
infectious diseases as well as to a decrease of the response to immunisation, potentially 
leading to an increased number of infections cases in the general population. In this regard, 
increases in the incidence of colds or influenza in occupational settings, as in the case of lead 
were reported31. Furthermore, exposure to certain immunotoxicants has been related to an 
increased incidence of neoplastic diseases or the development of certain autoimmune 
diseases; i.e. several studies have associated the occupational exposure to crystalline silica 
to rheumatoid arthritis, scleroderma, or systemic lupus erythematosus 32,33. Exposure to 
some organic solvents has been also described as a risk factor for developing autoimmune 
diseases such as scleroderma-like syndrome34,35. However, the findings from different 
studies on chemical-induced autoimmunity are not always consistent and further research 
may be needed to make definitive conclusions on these effects, at this point of time. Also it 
is extremely difficult to link the development of autoimmune diseases to a specific chemical, 
due to the complex nature of autoimmune diseases, i.e. genetic disposition and 
                                                            
31
 Horiguchi, S., et al. "Frequency of cold infections in workers at a lead refinery." Osaka city medical journal 38.1 (1992): 79. 
32
 Environmental health criteria 236. Principles and methods for assessing autoimmunity associated with exposure to chemicals (WHO, 
2006). 
33
 Cooper, Glinda S., Frederick W. Miller, and Dori R. Germolec. "Occupational exposures and autoimmune diseases." International 
immunopharmacology 2.2 (2002): 303-313. 
34
 Cooper, Glinda S., et al. "Evidence of autoimmune-related effects of trichloroethylene exposure from studies in mice and humans." 
Environ Health Perspect 117.5 (2009): 696-702. 
35
 Barragán-Martínez, Carolina, et al. "Organic solvents as risk factor for autoimmune diseases: a systematic review and meta-analysis." 
PloS one 7.12 (2012): e51506. 
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environmental factors. Besides, there may be long lag time before the disease is manifested, 
hence the link to the potential causal agent may be impossible to make. Cases of chemical 
exposure and immunostimulation effects have been also reported in the literature. For 
example, repeated dose 28-day oral toxicity studies in rats treated with hexachlorobenzene 
showed histomorphologic alterations, an increased lymphocyte migration activity, indicative 
of immunostimulation36. 
 In the case of neurotoxicants, exposure of humans may lead to changes in sensory function, 
motor function, and changes in the performance of learned behaviour, memory and 
cognitive impairment. The exposure to some neurotoxicants has also been discussed to be 
related to the development of progressive neurodegenerative diseases, e.g. Alzheimer's and 
Parkinson-like diseases; however, further research has been suggested to confirm this 
association since data on this topic is very scarce. In fact, some of the observed neurological 
disorders may actually originate from exposure during development. Although the 
development of the nervous system continues postnatally, developmental neurotoxicity for 
the purposes of hazard classification and the CLP regulation would fall in the category of 
reproductive toxicants and thus already be considered as SVHC according to Art 57 (c). 
4.1.2.  Irreversibility of health effects 
In the ECHA discussion paper on sensitisers, the irreversibility of effects is listed as a supportive 
criterion to identify a substance as SVHC, based on the fact that changes in the structure and/or 
function of the organ could be permanent. Irreversibility is estimated by the absence of a full 
recovery or by an incomplete recovery within the foreseen recovery periods of the respective test 
guidelines. 
 In the case of carcinogens and mutagens, adverse health effects e.g. development of cancer 
may lead to death or irreversible ill health. 
 In the case of reproductive toxicants (development), adverse health effect may be present in 
the form of irreversible malformations in children. 
 In the case of some immunotoxicants, reversibility of adverse effects has been observed and 
once the exposure to the substances ceases, the immune system is able to return to its prior 
status37. However, one of the concerns of immunosuppression effects is its association with 
an increased risk of cancer due to the failure of the immune system or to a higher risk of 
developing virus-induced neoplasias38. Even though there is evidence of a link between 
certain chemicals and immunosuppressive effects, it is important to note that some authors 
have reported that the data to support a causal relationship between the association of 
                                                            
36
 Schulte, Agnes, et al. "Two immunotoxicity ring studies according to OECD TG 407—comparison of data on cyclosporin A and 
hexachlorobenzene." Regulatory Toxicology and Pharmacology 36.1 (2002): 12-21. 
37
 Guidance for immunotoxicity risk assessment for chemicals (IPCS harmonization project document; no. 10). 
38
 Luster, Michael I., et al. "Relationships between chemical-induced immunotoxicity and carcinogenesis." Drug information journal 30.1 
(1996): 281-286. 
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certain cancers and chemicals with immunotoxic potential is insufficient, especially following 
exposure of adults39. Occupational exposure to chemicals such as certain solvents, crystalline 
silica or certain pesticides may influence the development of systemic autoimmune disease 
leading to irreversible effects 40 . These associations have been reported only in 
epidemiological or animal studies and are not always strong and clear. 
 In the case of neurotoxicants, adverse effects may be reversible or irreversible. The nervous 
system is known for having a functional reserve capacity. Its ability to return to the state 
prior to exposure, as well as its ability to compensate and adapt for neurotoxic insults is 
however limited and depends on the targeted cells, subcellular structures or 
neurotransmitters and the internal dose leading to neurotoxicity. Its capacity of 
regeneration following neuronal cell degeneration/death is absent or very limited and even 
though effects after single exposure to certain neurotoxicants may disappear when the 
exposure ceases, as in the case of certain organic solvents, this fact may not discard the 
presence of injuries or cell death. Also, in some cases exposure to neurotoxicants has been 
associated with chronic and irreversible diseases, e.g. long-term occupational exposure to 
certain organic solvent may induce encephalopathy, an irreversible damage to the central 
nervous system (mild to severe cognitive impairment that affects memory, attention, and 
psychomotor functions). Also chronic exposure to neurotoxicants may be linked with the 
development of neurodegenerative diseases41, which entail the irreversible loss of neuronal 
structure and functions, also defined as neurodegeneration 42 . For example, certain 
neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease have been 
discussed to be associated with exposure to metals or pesticides. Occupational exposure to 
heavy metals, e.g. manganese, iron, copper, mercury, zinc, and lead has been associated 
with neurological symptoms with similarities to Parkinson's disease such as weakness, bent 
posture, whispering speech, limb tremor, and salivation43,44. Furthermore, drinking water 
and occupational exposure to aluminium45,46 and other metals such as mercury and lead 
have been suggested to be a risk factor in Alzheimer's disease or the development of 
neuropathological (neurofibrillary tangles and senile plaques) and clinical symptoms 
(presenile dementia, reduced mental test scores) similar to those of Alzheimer's disease 47. 
                                                            
39
 Veraldi, Angela, et al. "Immunotoxic effects of chemicals: A matrix for occupational and environmental epidemiological studies." 
American journal of industrial medicine 49.12 (2006): 1046-1055. 
40
 Cooper, Glinda S., Frederick W. Miller, and Dori R. Germolec. "Occupational exposures and autoimmune diseases." International 
immunopharmacology 2.2 (2002): 303-313. 
41
 HPA CHaPD 001: Review of Environmental Chemicals and Neurotoxicity: Focus on Neurological Diseases (HPA, UK, 2007)  
42
 Cannon, Jason R., and J. Timothy Greenamyre. "The role of environmental exposures in neurodegeneration and neurodegenerative 
diseases." Toxicological Sciences 124.2 (2011): 225-250. 
43
 Gorell, J. M., et al. "Occupational exposures to metals as risk factors for Parkinson's disease." Neurology 48.3 (1997): 650-658. 
44
 Olanow, C. W. "Manganese-induced parkinsonism and Parkinson's disease." Annals of the New York Academy of Sciences 1012.1 (2004): 
209-223. 
45
 Flaten, Trond Peder. "Aluminium as a risk factor in Alzheimer’s disease, with emphasis on drinking water." Brain research bulletin 55.2 
(2001): 187-196. 
46
 Graves, Amy B., et al. "Occupational exposures to solvents and aluminium and estimated risk of Alzheimer's disease." Occupational and 
environmental medicine 55.9 (1998): 627-633. 
47
 Liu, Guijian, et al. "Metal exposure and Alzheimer’s pathogenesis." Journal of structural biology 155.1 (2006): 45-51. 
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Aluminium has been also described as a potent neurotoxicant and the causal agent of 
encephalopathy in patients that receive dialysis due to chronic renal failure48,49. 
During the BfR/BAuA workshop, some stakeholders commented that although some adverse effects 
may be reversible over time, the potential damage and social impact as a result of these temporary 
effects cannot be excluded (e.g. prolonged periods of illness, lower performance or accidents at 
work).  
In certain exposure scenarios it could be relevant to take also into account the impact that reversible 
effects may have on human health and on the determination of the level of concern. Reversible 
effects such as headache, dizziness, decrease of concentration, movement disorders in occupational 
settings in which operating dangerous machinery is required may raise a higher level of concern for 
their fatal consequences. These effects are normally a response to exposure concentrations eliciting 
acute effects. However, in some cases the reversibility of such effects may be so slow that these 
effects may raise a level of concern similar to irreversible effects. In general, a complicating issue is 
that the permanence (irreversibility) of effects (especially for immunotoxicity) may often not be 
demonstrated in standard guideline studies, and possibly be derived only from epidemiological data 
and generic medicinal knowledge on these aethiopathologies. 
4.1.3.  Delay of health effects 
Toxic effects of some substances may be only detected after a long period of time between the 
exposure and manifestation of the adverse effects. In this case, risk management measures may be 
not taken in time, and individuals might be exposed for a long period to chemicals for which 
potential health effects and risks are unknown. Delay of effects, although not a specific relevant 
factor for the identification of SVHCs, could be an important aspect to establish higher levels of 
concern. 
In addition, delay of effects of chemicals could be an important feature during early postnatal stages 
of life, in which systems affected are immature and effects can be expressed or observed only after a 
long period of time. In this case, it is often difficult to relate this effect to a chemical exposure and 
therefore it won't be recognise to be of concern. Toxicity testing may help in the identification of 
delayed effects, and taking appropriate risk management measures on time could avoid the 
potential risk posed by these chemicals. 
 In the case of carcinogens and mutagens, there are usually long delays before adverse effects 
manifest themselves.  
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 Alfrey, Allen C., Gary R. LeGendre, and William D. Kaehny. "The dialysis encephalopathy syndrome: possible aluminum intoxication." 
New England Journal of Medicine 294.4 (1976): 184-188. 
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 Wills, MichaelR, and John Savory. "Aluminium poisoning: dialysis encephalopathy, osteomalacia, and anaemia." The Lancet 322.8340 
(1983): 29-34. 
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 In the case of reproductive toxicants (development) there can be some delay before adverse 
effects manifest themselves.  
 In the case of immunotoxicants, depending on the mode of action and the time of exposure, 
both immediate and long delayed adverse effects could be expected. Depending on the dose 
and the observed effects, the immune system may have a capacity to return to normal 
status after exposure to immunotoxicants; however, immune dysfunction due to early 
postnatal exposure or during immune system maturation, may increase the later-life risk to 
certain autoimmune diseases and other health effects50 or immune dysfunction (e.g. by 
decreased defense against infections) may become obvious much later than the primary 
immunosuppressive effect. As mentioned previously, an increased risk of cancer might also 
be a potential delayed effect of exposure to immunosuppressant chemicals or a co-morbid 
effect of substances with chemical-induced autoimmunity effects51. 
 In the case of neurotoxicants, exposure of children to certain chemicals with neurotoxic 
effects may lead to delayed and permanent effects such as learning disabilities, sensory and 
memory deficits, and cognitive developmental delays. Also long-term low-level exposure has 
been related to a decrease in performance in neuropsychological functions; an increase of 
persistent developmental disorders, delays in cognitive development and attention deficit/ 
hyperactivity disorder52. In adults, short-term exposure to some organic solvents has been 
linked to transient symptoms that generally disappear when the exposure ceases; however, 
long-term exposure may result in the delayed effects (observed for organic solvents or when 
the neurotoxicants accumulates in the nervous tissues). A well-known example of delayed 
effects of neurotoxicants are the symptoms after exposure to some organophosphates 
which is also called 'organophosphate induced delayed polyneuropathy', a rare 
neurodegenerative disease that is characterised by the central and peripheral nervous 
system degeneration, followed by symptoms as ataxia and paralysis that may appear after 3 
weeks after exposure. Other toxic effects associated with exposure to organophosphates are 
the cholinergic syndrome (sweating, lacrimation, salivation, respiratory difficulties, tremors, 
ataxia), and the intermediate syndrome (respiratory difficulties due to malfunctions of 
respiratory muscles) that appear not delayed after exposure. Depression symptoms have 
been also reported after long-term occupational exposure to certain chemicals, such as 
certain pesticides 53 or carbon disulphide54,55. 
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 These effects would be considered as developmental effects and therefore be considered as SVHC.  
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 Dietert, Rodney R. "Role of developmental immunotoxicity and immune dysfunction in chronic disease and cancer." Reproductive 
Toxicology 31.3 (2011): 319-326. 
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4.2. Other considerations 
According to the ECHA discussion paper on sensitisers, other factors of concern to consider the 
identification of a substance under Art. 57 (f) are the impairment of quality of life, consequences for 
society and the difficulty to establish dose-response relationships for the risk assessment of these 
substances. 
The social impact of exposure to a substance may be determined at individual level (how the 
exposure and effects of this substance impacts on the regular life of an affected individual) or at 
societal level, regarding which are the social and economic implications for the population. 
In addition, the possibility to derive safe levels of exposure could be informative to decide the 'level 
of concern' of a substance and may be taken into consideration on a case-by-case basis for 
prioritisation. Exposure to chemicals for which safe levels can be derived may be controlled by risk 
management measures and lead to a lower level of concern. 
4.2.1.  Quality of life affected 
 In the case of carcinogens and mutagens, possible side-effects such as organ dysfunction can 
result in the person having to live with a long-term illness, limiting the possibility of living a 
normal working and private life. Regardless of the prognosis, the negative health effects 
caused by exposure to carcinogens and mutagens are generally considered to be a ‘serious’ 
consequence, as it always has the potential to be fatal. 
 In the case of developmental toxicants, depending on the effect manifested, the long-term 
consequences for the infants/person may be very severe and impair the quality of life. 
Children having developmental effects may need life-long medication and/or support during 
their daily life. There is also an indirect effect on the quality of life of such children’s parents 
in terms of emotional investment, care and financial resources needed. 
 In the case of immunotoxicants, long-term adverse health effects may appear after 
exposure, i.e. an increase risk to severe infections and/or cancer or irreversible autoimmune 
diseases. In these cases, the possibilities for affected individuals to live a normal life are 
limited and quality of life could be impaired for long periods. 
 In the case of neurotoxicants, exposure may lead to chronic diseases that need life-long 
treatment56,57. Also, at the workplace, exposure to neurotoxicants has been associated with 
a slow-down of the performance on reaction-time tasks or changes in vision58,59. For 
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 Alavanja, Michael CR, Jane A. Hoppin, and Freya Kamel. "Health Effects of Chronic Pesticide Exposure: Cancer and Neurotoxicity* 3." 
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Perspectives 112.9 (2004): 950. 
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example, long-term exposure to white spirit (longer than 10 years) may lead to the 
impairment of brain function and can therefore be associated with a high risk for the 
development of a chronic toxic encephalopathy60. 
It is important to note, that certain immunotoxic or neurotoxic effects if detected time after 
exposure, e.g. during childhood and adolescence, may originate from exposure during in utero 
development and should therefore be classified as neurodevelopmental toxicants (i.e. toxic for 
reproduction, R). Some substances may be immunotoxic and/or neurotoxic in adults and progeny, 
possibly at different dose levels. It has been suggested that immunotoxicity and neurotoxicity could 
occur at lower doses in postnatal developing organisms than in adults (see also 5.2). These effects 
are not examined in the test guidance used to reach the developmental toxicity classification. Each 
effect needs proper consideration with regard to the population group and hazard class.  
4.2.2.  Societal concern 
Societal concern is not considered a determining factor for the identification of substances as SVHC 
but it could provide relevant information about the level of concern of a substance, in particular 
about its effects at social and economic levels in society. 
 In the case of carcinogens and mutagens, there is widespread concern in society, due to the 
high prevalence of cancer in the worldwide population and the uncertainty surrounding 
future effects that may be persistent, e.g. development of cancer and potential death. There 
can be a high cost of treating affected individuals in society. 
 In the case of developmental toxicants, the potential adverse health effects on children e.g. 
severe malformations or restrained intellectual capabilities are of high concern for the 
society. There can also be a high cost of treating affected individuals in society. 
 In the case of immunotoxicants, substances with immunosuppressive mechanisms, which 
may result in an increased risk of incidence of neoplasms (due to immunosuppression), may 
give rise to a similar level of concern as carcinogens. Also a decrease in host resistance and 
an improper response to vaccination are primary effects of concern because of public health 
implications: the spread and increase of infectious diseases such as cold and influenza 
generate costs related to increased sick leave or absences from work, costs in health care 
goods and services, and loss of productivity at the workplace. Furthermore, autoimmune 
chemical-related diseases are in general chronic; thereby it may imply a lifetime cost for the 
health system61. 
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 In the case of neurotoxicants, the levels of concern to chemical exposure are based on the 
magnitude of effect, duration of the exposure and reversibility of some neurotoxic effects. 
Of particular concern is the fact that few chemicals have been evaluated for neurotoxicity as 
well as the lack of research on the relationship between adverse effects and exposure to low 
concentrations of neurotoxicants and its potential impact on the society62. As mentioned, 
neurotoxic effects at the workplace may be very serious and may lead to significant financial 
losses resulting from health problems63. 
4.2.3.  Is derivation of a ‘safe concentration’ possible? 
The possibility to derive safe concentrations is not a decisive factor during the process to identify a 
chemical as SVHC, as the identification of SVHC is based on hazard; however, this information could 
be relevant and may be taken into consideration on a case-by-case basis. Exposure to chemicals 
whose safety levels can be derived may be controlled by later risk management measures. 
 In the case of non-threshold carcinogens and mutagens, it is only possible to conclude ‘zero 
risk’ if there is no exposure. In certain cases, even very small doses of such substances can 
cause adverse effects, which may only manifest after several years of exposure. 
Consequently, derivation of a safe concentration is normally not possible, except in few cases 
of non-genotoxic carcinogens. 
 In the case of developmental toxicants, it is normally possible to determine a toxicological 
threshold and consequently a safe concentration. 
 In the case of immunotoxicants, it is normally possible to derive a dose-response 
relationship for immunosuppression; however, the calculation of this dose-relationship 
depends on the mode of action of the chemical and the considered endpoint. In this regard, 
and bearing in mind the lack of scientific consensus in this topic, some researches have 
suggested that certain immunotoxic end-points may follow a non-monotonic dose-response 
curve, in which effects produced at low doses are opposite to those exerted by high doses 
(also called 'hormesis effect'). An example for this is the effect of methylmercury in the 
response of peripheral blood lymphocytes to phytohaemagglutinin, where in rats high-doses 
produce suppression and low-doses produce stimulation of this parameter64. Therefore, 
'safe concentrations' may vary not only depending on the substance but also on the immune 
parameter considered which might be important information in particular cases. 
 In the case of neurotoxicants, it is possible to establish safe levels of exposure in most of the 
cases, but the same issues with potential hormesis effects as described above can be found 
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in the literature for some chemicals showing neurotoxic effects including polychlorinated 
biphenyls or heavy metals such as mercury or aluminium 65,66. Although a safe concentration 
may exist theoretically, some neurotoxicants (such as lead)67 are hazardous at extremely low 
concentrations that are already exceeded by environmental exposure. 
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5. Specific considerations 
5.1. Potency 
In the previous ECHA discussion paper, potency was discussed as a potential supporting factor, 
specific for sensitisers, when evaluating the level of concern during the process of identification of 
SVHC. Potency may be a factor to be considered since potent immunotoxicants or neurotoxicants 
may evoke adverse effects at lower exposure levels. Similarly to sensitisers, potent immunotoxicants 
or neurotoxicants are suggested to be prioritised over less potent toxicants, since less potent 
toxicant will give rise to a lower concern than toxicants with high potency. Toxicity of substances, 
and as consequence potency, is based on a description of the dose-effect relationship values which 
could be used as a measurement of toxic potential and to set exposure limits68. However, in contrast 
with the case of sensitisers (e.g. EC3 derivation from murine local lymph node assay test (LLNA) 
values) 69 , there are no established values or tests for potency evaluation of immune and 
neurotoxicants. The guidance values as defined in the CLP criteria70 for STOT-SE/RE category 1and 2 
(see classification could be used for hazard identification and classification but also as potency 
indication. 
5.2. Groups at risk to immunotoxicant and neurotoxicant exposure 
In order to evaluate the social impact of some chemicals, it is important to take into consideration 
the group of the population at higher health risk due to exposure to these substances. In certain 
cases, some individuals of the population such as children and pregnant women are usually 
considered groups at risk71. In other cases, determinant characteristics of a group of people could 
lead to a higher risk for particular chemicals. Age, an immunocompromised state or genetic 
susceptibility are some of these characteristics. 
5.2.1. Age 
Age-related difference to exposure to chemicals could be linked not only to differences in exposure 
and accumulation over time but also differences in susceptibility to substances. In the elderly 
population, immunosenescence, an age-related dysfunction of the immune system, together with 
other factors such as malnutrition and age-associated physiological changes have been related to an 
increase of the susceptibility to infectious diseases, and a decrease in the response to 
vaccination72,73,74. Also, it has been suggested that the elderly could be more susceptible to chemical 
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insults and have a reduced capacity to respond to new toxic perturbations, and to compensate 
previous exposures. Previous exposure to neurotoxicants has been related with the development of 
some neurodegenerative diseases in the aged population. 
5.2.2. Developmental immune and neurotoxicity  
The focus of this paper is immunotoxicity and neurotoxicity in adults; however, in order to 
understand more the consequences of these chemicals it is necessary to take into consideration 
some information on developmental immune- and neurotoxicity, even though these effects are 
specifically covered under toxicity for reproduction. Effects may be diagnosed a long period after 
birth, and therefore it is an important factor to be discussed in this paper. 
It is not explicit if developmental neurotoxicity and immunotoxicity occurring solely as a result of 
exposure during childhood (and not prenatal or via lactation) is covered by developmental toxicity. 
CLP Regulation 1272/2008 (Annex I, 3.7.1.4) states that Developmental toxicity includes, in its widest 
sense, any effect which interferes with normal development of the conceptus, either before or after 
birth, and resulting from exposure of either parent prior to conception, or exposure of the developing 
offspring during prenatal development, or postnatally, to the time of sexual maturation. However, it 
is considered that classification under the heading of developmental toxicity is primarily intended to 
provide a hazard warning for pregnant women, and for men and women of reproductive capacity. 
Therefore, for pragmatic purposes of classification, developmental toxicity essentially means adverse 
effects induced during pregnancy, or as a result of parental exposure. Therefore, the hazard 
statement of the label covers only the unborn child. 
Similar to the elderly, the children's immune and neural system could be more susceptible to 
chemicals than that of adults. Substances exerting these effects may be referred to as 
developmental immunotoxicants or neurotoxicants are considered substances toxic for reproduction 
even though effects may be diagnosed long periods after birth, and therefore it is an important 
factor to discuss them in this section. Toxicity during development may be more severe due to 
several factors such as the rapid organ development or/and increased absorption rates; exposure to 
higher doses (considering dose per kg body weight), and the possibly reduced capacity of 
detoxification for xenobiotics. In some cases, even low exposure levels may result in long-lasting 
effects that will become evident with age. 
In the case of immunotoxicants, it is generally believed that the immature immune system is more 
susceptible than the fully mature system and sequels could be more persistent. Maturation of the 
immune system is a critical and sensitive process that may be affected by exposure to 
immunotoxicants. Effects during maturation may lead to a lifelong dysfunctional immune system. In 
children, diseases as leukaemia, influenza, asthma, type 1 diabetes and allergic diseases have been 
associated with exposure to immunotoxicants during the developmental stage. In contrast, in adults 
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disturbance of the immune system normally requires higher doses and in comparison to 
developmental immunotoxicity such effects are more likely to be reversible75. 
In the case of neurotoxicants, the developing brain is more vulnerable than an adult brain. Indeed, 
exposure during early foetal development can cause brain injury at doses much lower than those 
affecting adult brain functions. Exposure to chemicals in the environment during early foetal 
development76 has been associated with development of neurodevelopmental disorders such as 
motor and sensory deficits, developmental delays, learning disabilities, attention deficit disorder, 
mental retardation or autism77. 
5.2.3. Immunodeficiency 
Exposure to chemicals that in a healthy population would pose mild or moderate changes in the 
immune system response may cause severe effects in individuals with a challenged immune system. 
5.2.4. Genetic susceptibility and gender 
Genetic predisposition in the population may be a factor to consider especially when evaluating 
chemicals with immunotoxic or neurotoxic effects. Susceptibility to some effects or disorders may 
increase with the presence of congenital defects, and in some cases the genetic predisposition of an 
individual could be a determinant factor, as in the case of some chemically-induced autoimmune 
disorders. 
Another influential factor to consider is the gender bias that some immune diseases exhibit. 
Exposure to immunotoxicants during postnatal early-life stages may produce differences in response 
depending on the gender. This fact is notable in the case of predominance of some autoimmune 
diseases78, particularly in women; in fact it has been reported that under certain conditions 
(thyroiditis, scleroderma, and systemic lupus erythematous) more than 85% of patients are female79. 
The evaluation of the impact of certain chemicals on the immune system (with exception of 
sensitisers) is a challenging task that has led to the controversy whether small changes in the 
immune function may be significant and used to assess the risk of exposure to immunotoxicants in 
human populations. In the case of neurotoxicants, the sensitivity to neurotoxicants varies across the 
general population although the reasons for this variability are still unknown80. 
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6. Conclusions 
An evaluation of relevant factors to compare an 'equivalent level of concern' to carcinogenic, 
mutagenic or reprotoxic substances has been performed for substances classified as STOT-SE/RE 
(category 1 and 2), particularly for substances showing immunotoxic or neurotoxic effects. This 
evaluation follows the criteria proposed by different stakeholders as considered previously in the 
ECHA's discussion paper on sensitisers, and includes the following factors: the type of possible 
health effects, the irreversibility and the delay of such effects. 
The evaluation suggests that some substances showing severe immunotoxic or neurotoxic effects 
following single or repeated exposure could present an 'equivalent level of concern' as CMRs and 
potentially be identified as SVHC according to the Art. 57(f) route in REACH. For both, neurotoxic and 
immunotoxic substances a case-by-case justification considering hazard assessment and evidence of 
an equivalent level of concern is necessary. 
Neurotoxic effects include motor and sensor activity alteration, effects on reflex action or effects on 
cognition. After acute exposure, these effects may be transient, and therefore, some substances 
causing these effects may not be considered as potential SVHC candidates according to Article 57(f); 
however, long-term exposure with slowly reversible effects or delayed effects may lead to 
irreversible damage of the nervous system resulting in serious chronic diseases, e.g. encephalopathy, 
neurodegenerative diseases, and cognitive impairment. 
Also some chemicals causing immunotoxic effects could be seen as potential SVHC candidates. 
Immunosuppression is normally reversible but long-term exposure may result in secondary effects, 
e. g., increased risk of infections or development of tumours. Also, a number of autoimmune 
diseases have been associated with long-term chemical exposure or suggested to arise as delayed 
effects following an exposure during a critical time window; however, the identification of these 
chemicals may be problematic due to the very complex nature of these diseases. 
In both, immunotoxic and neurotoxic effects, the relationship between chemical exposure and effect 
may not always be obvious. In general, identification of SVHC that exert immunotoxic effects is more 
complex than of substances with neurotoxic effects. The reason is, that no specific EU methods or 
OECD test guidelines are available to characterise immunotoxic properties and information on 
immunosuppression, immunostimulation or autoimmune diseases is mainly retrieved from non-
standard tests. 
As stated in Art. 57 (f), the only determining factor for the identification of substances as SVHC, is 
the existence of scientific evidence of probable serious effects, which give rise to an equivalent level 
of concern to CMR substance. However, other factors as discussed in the BfR/ BAuA workshop on 
REACH Article 57(f) and as presented in the ECHA discussion paper on sensitisers may provide 
relevant information about the level of concern of a substance to be taken into consideration in the 
case-by-case evaluation of these chemicals, such as the impairment of quality of life, consequences 
for society and the difficulty in performing risk assessments. 
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In this regard, societal concern and impairment of quality of life can be a consequence of exposure 
to neurotoxicants or immunotoxicants particularly for vulnerable population. In addition, in some 
cases the derivation of safe threshold levels could be difficult for both neurotoxicants and 
immunotoxicants; however in general it is possible and risks can be controlled under different risk 
management options. Potency, age, genetic susceptibility and gender are considerations that may 
be taken into account when evaluating the level of concern. In this case, groups at higher risk to 
immunotoxicant and neurotoxicant exposure include children and elderly as well as people with a 
challenged immune system, which may be more sensitive to lower concentrations. 
In conclusion, neurotoxicity or immunotoxicity effects occurring at dose ranges, which are critical for 
the respective STOT classification (STOT-SE or STOT-RE, category 1 and 2) should be primarily 
considered for SVHC identification. In agreement with the previous discussion paper on sensitisers, 
this document underlines the importance of a harmonised classification as STOT substance for these 
specific effects before starting any SVHC identification, followed by a case-by-case 'equivalent level 
of concern' evaluation and justification. 
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Annex I: STOT classification in CLP and Criteria for STOT classification 
STOT classification encompasses several adverse effects that may be severe, delayed and/or 
irreversible, including haemotoxicity, hepatotoxicity, nephrotoxicity, neurotoxicity and 
immunotoxicity, but also transient effects as respiratory tract irritation and narcotic effects. As a 
starting point, JRC assessed the endpoints immunotoxicity and neurotoxicity. 
In the Regulation (EC) No 1272/2008 and the Guidance to the Regulation on classification, labelling 
and packaging (CLP) of substances and mixtures, STOT classification for Category 1 and 2 depends on 
whether the adverse outcomes are significant or relevant, or whether they are severe, thereby 
having a significant impact on human health (see summary in table below). This evidence could be 
based on human studies; e.g. case reports, epidemiological studies, medical surveillance and 
reporting schemes and information from national poisons centres, and/or based on animal studies 
that on many occasions could be more informative than human cases, since animal studies are 
conducted under controlled conditions respecting exposure and other experimental settings. 
As mentioned in the guidance, weight-of-evidence and expert judgement are required to properly 
classify a substance under STOT categorisations. CLP regulation provides dose/concentration 
guidance values to be used as part of a weight-of-evidence evaluation and to assist in the 
classification of STOT substances in Category 1 or 2 (see Table A.1 below). In addition, STOT-SE and 
STOT-RE categories are derived from significant data on non-lethal toxic effects from acute toxicity 
testing and 28 or 90-day repeated-dose studies, respectively81. 
Other relevant evidences from studies in humans and/or animals to be considered as listed in the 
CLP Regulation 1272/2008 (Annex I: 3.9.2.7.3) to support STOT classification are: 
(a) morbidity or death resulting from repeated or long-term exposure. Morbidity or death may result 
from repeated exposure, even to relatively low doses/concentrations, due to bioaccumulation of the 
substance or its metabolites, and/or due to the overwhelming of the de-toxification process by 
repeated exposure to the substance or its metabolites. 
(b) significant functional changes in the central or peripheral nervous systems or other organ 
systems, including signs of central nervous system depression and effects on special senses (e.g., 
sight, hearing and sense of smell). 
(c) any consistent and significant adverse change in clinical biochemistry, haematology, or urinalysis 
parameters. 
(d) significant organ damage noted at necropsy and/or subsequently seen or confirmed at 
microscopic examination. 
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(e) multi-focal or diffuse necrosis, fibrosis or granuloma formation in vital organs with regenerative 
capacity. 
(f) morphological changes that are potentially reversible but provide clear evidence of marked organ 
dysfunction (e.g., severe fatty change in the liver). 
(g) evidence of appreciable cell death (including cell degeneration and reduced cell number) in vital 
organs incapable of regeneration. 
In the next section, specific adverse effects of immunotoxicants and neurotoxicants significant for 
STOT classification are discussed. 
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Table A 1. Criteria and guidance values82 to assist in Category 1 and 2 classifications for STOT-SE and STOT-RE83 
 STOT-SE Cat. 1 STOT-SE Cat. 2 STOT-RE Cat. 1 STOT-RE Cat. 2 
Criteria Significant toxicity in humans or 
potential to produce significant 
toxicity in humans following single 
exposure 
Presumed to have the potential 
to be harmful to human health 
following single exposure 
Significant toxicity in humans or 
potential to produce significant 
toxicity in humans following 
repeated exposure 
Presumed to have the potential to 
be harmful to human health 
following repeated exposure 
Basis of evidence Human cases or epidemiological 
studies or observations in 
experimental animals with 
significant and/or severe toxic 
effect, of relevance to human 
health 
Studies in experimental animals, 
of relevance to human health 
 
Human cases or epidemiological 
studies or observations in 
experimental animals with 
significant and/or severe toxic 
effect, of relevance to human 
health 
Studies in experimental animals of 
relevance to human health 
 
Observations  Significant non-lethal effects 
observed in acute toxicity testing 
Significant non-lethal effects 
observed in acute toxicity testing 
Significant toxic effects observed in 
90-day repeated-dose animal 
studies, in rats (oral) or rabbits 
(dermal) 
Generally low exposure 
concentrations 
Significant toxic effects observed in 
90-day repeated-dose animal 
studies, in rats (oral) or rabbits 
(dermal) 
Generally moderate exposure 
concentrations 
Proposed guidance 
values  
 
C ≤ 300 (oral)  
C ≤ 1000 (dermal) 
(mg/kg bw) 
2000 < C ≤ 300 (oral) 
2000 < C ≤ 1000 (dermal) 
(mg/kg bw) 
C ≤ 10 (oral) 
C ≤ 20 (dermal) 
(mg/kg bw/d) 
10 < C ≤ 100 (oral) 
20 < C ≤ 200 (dermal) 
(mg/kg bw/d) 
Proposed guidance 
values, inhalation 
(gas) 
C ≤ 2500 (gas) 
(ppmV/4h) 
20000 < C ≤ 2500 (gas) 
(ppmV/4h) 
C ≤ 50 (gas) 
(ppmV/6h/day) 
50 < C ≤ 250 (gas) 
(ppmV/6h/day) 
Proposed guidance 
values, inhalation 
(vapour)  
(dust/mist/fume) 
C ≤ 10 (vapour) 
C ≤ 1.0 (dust/mist/fume) 
(mg/l/4h) 
20 < C ≤ 10 (vapour) 
5.0 < C ≤ 1.0 (dust/mist/fume) 
(mg/l/4h) 
C ≤ 0.2 (vapour) 
C ≤ 0.02 (dust/mist/fume) 
(mg/l/6h/day) 
0.2 < C ≤ 1 (vapour) 
0.02 < C ≤ 0.2 (dust/mist/fume) 
(mg/l/6h/day) 
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Annex II: Adverse health effects caused by immunotoxicants and 
neurotoxicants 
A.2.1. Adverse immune system effects 
The immune system is a complex system that provides the body with a proper balance of the 
immune response, including host defence against pathogens or neoplasias; response to foreign 
compounds, and recognition and discrimination of self from non-self body components. 
Immunotoxicology investigates how substances can interact, alter, and compromise the immune 
system function contributing to a wide range of adverse effects from mild to severe. Substances can 
affect the immune system evoking a combination of adverse outcomes including 
immunosuppression, allergies, hypersensitivity reactions, higher risk to develop autoimmune 
diseases and dysfunctional anti-inflammatory responses84. The seriousness of these effects depends 
on the mode of action, severity of damage on immune system (including all immune tissues) and 
vulnerability of the population exposed as well as the time of exposure to the chemicals. 
Among the adverse immunotoxic effects, immunosuppression, immunostimulation and autoimmune 
response have been taken into consideration as potential outcomes to be relevant for identification 
of SVHC. Immunological effects such as allergies or hypersensitivity reactions are classified under 
another CLP category, and have been previously discussed.  
 Immunosuppression:  
Exposure to chemicals with immunosuppressant effects may lead to an increased risk of 
incidence of neoplastic diseases, an increase of the susceptibility and potential severity of 
infectious diseases, and/or a decrease in the response and effect of immunisation, having as 
a possible consequence also the increase in the number of incidence of infection cases in the 
general population. 
Although an increased risk to certain types of cancer has been linked to a decreased 
effectiveness of the immune system in eliminating neoplastic cells or virus- related 
neoplastic events, cancer has also been described as a co-morbid adverse effect related with 
other chronic immune-based diseases, especially those as a consequence of developmental 
immunotoxicity. Regarding changes in host resistance (to tumour cells, bacteria, viruses), 
adverse effects may be mild or severe, even lethal, depending on the exposure 
characteristics and vulnerability of the population exposed. Usually, in healthy populations, 
small changes in resistance to infections will lead to mild to moderate adverse effects, 
whereas they could be severe in individuals with immunodeficiency diseases or under 
immunosuppressive therapy. 
Cellular changes such as atrophy or decreases in population of T-cell or B-cell compartments 
can directly be seen in animal studies (detection can be improved by specific methods that 
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are not standard). The proof of dysfunction of the innate, nonspecific immune responses 
against infections, is rarely available in regulatory datasets. Testing on specific immune 
responses is even more rarely found. 
 Immunostimulation: 
Effects due to alterations by immunostimulation are not very well understood, and usually 
difficult to evaluate; they may exacerbate allergic reactions, worsening autoimmune disease 
and induce or amplify inflammatory response causing organ damage.  
 Autoimmunity: 
Autoimmunity and autoimmune diseases result from altered immune responses against self-
molecules. The immunological effectors and mechanisms involved in autoimmune reaction 
are the same of those associated with responses to foreign antigens, including activation of 
the innate and adaptive immune systems, production of inflammatory mediators and 
activation of T lymphocytes or the generation of antibodies with specificity for self-antigens. 
A number of chemicals have been identified as potential triggers of autoimmunity and linked 
to an elevated risk to some systemic autoimmune diseases (scleroderma-like disease, 
Raynaud phenomenon, and systemic lupus erythematosus). However, the identification of 
chemical-associated autoimmune effects is challenging since autoimmune diseases are 
complex disorders, not yet well understood. Studies in animals exposed to substances 
showing autoimmunogenic potential (e.g. some metals, dioxins, or some pesticides), 
presented cellular, biochemical and clinical alterations similar to known autoimmune 
diseases85. 
Evaluation and identification of immunotoxic effects are not easy tasks. Adverse effects of some 
chemicals have shown clinical features similar to several autoimmune diseases; however, chemicals 
inducing autoimmunity are difficult to identify due to the lack of validated models and strategies. 
Furthermore, the immune system is present in nearly each tissue of any organ and alterations may 
lead to other organ dysfunctions that by default are not considered as cause of a failure of the 
immune system. Thus, in most cases the application of a weight-of-evidence approach by experts, 
on the available data is required. 
Currently, the identification of immunotoxicity effects is carried out using in vivo, repeated-dose 
toxicity in rats or mice, and in vitro studies, from which a broad range of parameters are measured. 
This list of factors include haematology changes, lymphoid organ weights, histopathology of 
lymphoid tissues and tissues where immune complexes may deposit, bone marrow cellularity, 
distribution of lymphocyte subsets and NK-cell activity or primary antibody response to T-cell 
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dependent antigen, as well as alterations in the immune function or characterisation of host 
resistance response 86. 
A.2.2. Adverse effects of neurotoxicants 
The nervous system is a complex organ system that controls several functions including sensory, 
motor and cognitive function. 
The OECD guidance for "Neurotoxicity Study in Rodents" (TG 424)87 describes neurotoxicity as an 
adverse change in the structure or function of the nervous system, central and peripheral that results 
from exposure to a chemical, biological or physical agent. In this definition, an adverse change 
should be considered any detrimental effect that affects the normal function of the nervous system 
resulting from single or repeated exposure. Furthermore, a group of experts on neurotoxicity risk 
assessment for human health from the WHO Environmental Health Criteria Programme have divided 
neurotoxic effects in two types, structural and functional88: Structural neurotoxic effects are defined 
as neuroanatomical changes occurring at any level of nervous system organization. These changes 
may be indicated by changes in brain morphology or weight, or histologic changes at tissue and 
cellular level. Functional changes are defined as neurochemical, neurophysiological or behavioural 
effects. These effects include adverse changes in somatic/autonomic, sensory, motor and cognitive 
function, and may be traced by changes in neurophysiological endpoints such as changes in nerve 
conduction, sensory potential or electrocephalographic pattern; in behavioural and neurological 
endpoints such as headache, dizziness, unconsciousness, seizures, cognitive problems, memory 
problems, and memory loss, behavioural, alteration of motor control, changes in learning, memory 
or attention. 
In a report, published by EFSA in 2012, on Identification of Cumulative Assessment Groups of 
Pesticides, the authors grouped the effects on the nervous system in effects concerning functional 
changes related to the motor division (including movement of muscles, effects of locomotion and 
neuropathy), effects on reflex action, hypertrophy/ hyperplasia in the brain, cell degenerations and 
neoplasms in the brain89. 
Neurotoxicity not only includes effects on the central nervous system but also neurotoxic effects 
(morphological or functional or both) on the eye (retina, eye nerve), ear (hearing), the sense of smell 
and the peripheral nervous system, considered serious damage of organs. A major problem is that 
examinations in the standard OECD test guideline are often not sufficient for the hazard 
characterisation or even identification of these effects. Moreover, indications coming from human 
observations remain only as indicators since a causal link between exposure and effects is often 
difficult to establish. 
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Some effects of short-term or acute exposure may be detected early after the exposure, whereas 
long-term exposure to relatively low-concentrations may result in impairment of the functional 
capacity of the nervous system where can only be detected after a long period of after exposure. In 
the latter case it is not always easy to establish a causal link between exposure and effects, or 
between patterns of exposure or dose. In these cases, integration of hazard characterisation, dose-
response analysis and exposure assessment as well as expert judgment of the data available is 
necessary. 
  
 43 
 
Annex III: Examples for chemicals with potential neurotoxic effects 
A number of chemicals such as some metals, pesticides and organic solvents have been associated 
with effects on the nervous system. The severity of these effects can range from mild to severe and 
it is also important to note that the absence or limited capacity of regeneration of the nervous 
system, especially in some neuronal regions, increases the level of concern of potential changes that 
can occur in the system. Some of the effects associated with these chemicals are presented in this 
Annex: 
A.3.1. Metals  
Long-term exposure to certain metals can lead to neurotoxic effects. Welders have been associated 
with a higher risk to suffer some neurological dysfunctions than welders not exposed to these 
metals. For example, some occupational studies in workers in foundries90 or exposed to welding 
fumes91,92 suggested a link between the chronic inhalation to aluminium with pre-clinical mild 
cognitive disorder which might prelude Alzheimer's disease and evoke delays in reaction time of 
exposed workers. Also, some epidemiological studies of drinking water with high content of 
aluminium have suggested the exposure to high levels of this metal as an important risk factor in the 
pathogenesis of Alzheimer’s type disease93. Biochemical changes related with exposure to high levels 
of aluminium such as formation and accumulation of amyloid beta protein, and aggregation of 
microtubullar protein tau forming neurofibrillary tangles may contribute to the loss of neurons in 
the hippocampus (symptoms of mild impairment in verbal memory). Aluminium pot-room workers 
have presented incoordination, intention tremor and cognitive deficits. Other symptoms often 
reported were loss of balance, memory loss, joint paint, dizziness, numbness and severe weakness. 
Other study showed the prevalence of neurological symptoms as incoordination and depression. 
Exposure to lead has also been associated with decline in cognitive function (after acute or longer-
term exposure), contribution to cognitive and behavioural impairments94 and to induction of 
neuropathy95. 
The nervous system is the principal target tissue affected by methylmercury in adults. Chronic 
exposure to organic forms of mercury such as the lipid-soluble form of mercury has been reported 
to perturb neuromotor, behavioural and cognitive functions96. 
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A.3.2. Pesticides 
Exposure to certain pesticides has been associated with an increased risk for behavioural and 
neurological long-term outcome. For example some insecticides, including certain 
organophosphates, carbamates, pyrethroids, or organochlorines interfere with chemical 
neurotransmission or ion channels, and usually cause reversible neurotoxic effects, that could 
nevertheless be lethal. Exposure to some of these chemicals has been associated with an increased 
risk to develop Parkinson's disease97,98. Parkinson's disease is a progressive degeneration of 
dopaminergic neurons of the substantia nigra pars compacta that project to the striatum and play a 
role in controlling motor functions. Effects similar to those evoked in Parkinson's disease as rigidity, 
resting tremors, bradykinesia and postural instability as well as others such as cognitive impairment, 
sleep disturbances, olfactory dysfunction and depression have been reported after poisoning or 
episodes of accidentally high exposure to these pesticides99. 
It is important to note that the association between the exposure to pesticides and 
neurodegenerative diseases as Alzheimer's disease and Parkinson's disease is under scientific debate 
since epidemiological studies present some evidence of these links but the data available are 
insufficient to support a causal relationship between the exposure to a particular pesticide or 
mixture and these diseases. 
A.3.3. Organic solvents 
Several organic solvents have been identified as having neurotoxic effects. Iregren and Gamberale 
(1995) investigated experimentally the potential neurotoxicity of different single and mixtures of 
organic solvents (such as methyl butyl ketone, styrene, toluene, white spirit, or xylene) and also 
reviewed effects of solvents investigated by other labs (e.g. formaldehyde, acetone or methyl ethyl 
ketone). The authors concluded that exposure to organic solvents were generally slight, transient, 
narcotic effects that resulted in prolonged delayed responses in behavioural tests. In the CLP 
Regulation, these effects are covered by STOT-SE Cat. 3 as transient target organ effects (Annex I: 
Table 3.8.1) that, may range from slight dizziness to deep unconsciousness and it gives as an example 
the organic solvent toluene to illustrate this category (CLP 3.8.6.1.4 Example 4: Toluene). 
Furthermore, these authors also noted that the effects resulting from long-term exposure to these 
chemical in occupational settings were not very specific and mainly diffuse symptoms as fatigue, 
memory impairment or reduction in intellectual functions100.  
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For white spirit (solvent and thinner in paints) the RAC (Risk Assessment Committee)101, in 
agreement with the assessments of the International Programme on Chemical Safety (IPCS 1996)102 
and Scientific Committee on Occupational Exposure Limits (SCOEL 2007)103 concluded in 2011 that 
long-term exposure (> 10 years) may lead to the impairment of brain function and can therefore be 
associated with a high risk for the development of a chronic toxic encephalopathy. In their view the 
corresponding decline in the number of diagnosed CTE (chronic toxic encephalopathy) cases with 
the decreasing use of solvent-based paints supports the theory of white spirit as the causative agent. 
RAC decided for a classification with STOT-RE 1 - H372 (Causes damage to the central nervous 
system through prolonged or repeated exposure). In that case the available animal data were 
inconclusive and failed to provide a molecular mechanism that could explain the long-term effects. 
The adverse effects as measured in humans are related to behavioural changes and may be difficult 
to detect in animals. 
Other examples of neurotoxicity include the toxicity to senses. Ethylbenzene104 was classified for its 
ototoxicity with H373 (May cause damage to hearing organs through prolonged or repeated 
exposure). Evidence is provided by one oral animal study, where high doses caused strong hair cell 
death in cochleae. There are no specific data on neurotoxicity in humans with mono-exposure to 
ethylbenzene. However, for other aromatic solvents (e.g. for toluene, xylenes or styrene) there is 
evidence for neurotoxicity in humans and strong experimental evidence for ototoxicity. A high 
frequency of hearing loss in workers involved in the production of paints and varnishes (containing 
the following mixture constituents: ethylbenzene, xylene and trimethylbenzene isomers) was 
described by Sulkowski et al. (2002)105. 
As pointed out in the case of immunotoxicants, the role of experts for the interpretation and weight-
of-evidence based determination is essential, as many neurological tests are qualitative and 
descriptive, which may complicate their evaluation and the comparison of results. According to the 
US-EPA, during the evaluation of neurotoxicity of pesticides, the overall toxic profile including hazard 
identification and characterization as well as information on the mode of action may be considered 
in the weight-of-evidence approach. To establish the toxicological profile for neurotoxicants, various 
endpoints may be measured including neuropathological, neurochemical, neuropsychological and 
behavioural characteristics to provide information about potential effects of chemicals on peripheral 
and central nervous system; these tests evaluate the toxicity in sensorial organs, neuromuscular 
effects, learning and memory capacity and histopathology changes of the nervous system.  
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